APEIRON Biologics AG Closes Regional License Agreement for Antibody-based Immunotherapy

Apeiron today announced the closing of a transaction with Paladin Labs Inc. (Canada) in its ongoing initiative to out-license APN311, an antibody-based immunotherapy in development for the treatment of children with high-risk neuroblastoma.

Press release

Presseaussendung